Skip to main content
OpenTrials
Completed

NCT Number: NCT07297719

Evaluation of Glistening, Visual Outcomes and General Safety 24 Months Post-IOL Implantation

Main evaluation of glistening at least 24 Months post-IOL implantation

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Aier Eye Hospital of BoAo Hope City

Hainan, China

About this study

Evaluation of glistening, visual outcomes and general safety after at least 24 Months post-IOL implantation

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients currently implanted with the CT LUCIA 621P IOL into the capsular bag in at least one eye and who participated in previous study "CT LUCIA 621P-BER-401-21";
  • A minimum follow-up period of 24 months after the IOL implantation of the study eye (selected as the study eye in the previous study);
  • Patients willing and capable of providing informed consent;
  • Patients willing and capable of complying with visits and procedures as defined by this protocol.

Exclusion criteria

  • Complications during cataract surgery with clinically significant impact;
  • Postoperative clinically significant corneal or retinal pathology as well as postoperative acute or chronic inflammatory ocular conditions (e.g. uveitis, iritis etc.);
  • Presence of clinically significant PCO with potential to limit the glistening evaluation;
  • IOL dislocation (the complete IOL is not stable fixated in the capsular bag);
  • Patients unable to meet the limitations of the protocol or likely of non-cooperation during the clinical investigation;
  • Patients whose freedom is impaired by administrative or legal order.

Treatment and study plan

Primary outcomes

  1. Glistening Count

    Time frame: single study visit conducted 24 months after IOL implantation of the study eye

    Glistening count: Number of glistenings (=microvacuoles) in the illuminated field were counted by slit lamp examination at the study visit 24 months post IOL implantation of the study eye. Lower glistening counts indicate a better outcome (=fewer glistenings).

  2. Glistening Density Evaluation

    Time frame: single study visit conducted 24 months after IOL implantation of the study eye

    Glistening density evaluation: Number of glistenings in the illuminated field were counted by slit lamp examination at the study visit 24 months post IOL implantation of the study eye. The number of glistenings were recorded and the density of microvacuoles per square millimeter (MV/mm²) was calculated. Lower glistening density values indicate better outcome (=fewer glistenings).

  3. Glistening Grading (Miyata Classification)

    Time frame: single study visit conducted 24 months after IOL implantation of the study eye

    Glistening grading (Miyata classification): At the 24-month post-IOL implantation visit, the number of glistenings/microvacuoles (MV) in the illuminated field of the study eye was counted by slit-lamp examination. Glistening density was expressed as microvacuoles per square millimeter (MV/mm²) and graded using the Miyata Glistening Density Grading Scale (grades 0-3), where the minimum glistening level corresponds to grade 0 (<25 MV/mm²) and the maximum to grade 3 (101-200 MV/mm²).0 corresponds to <25 MV/mm² and grade 3 to 101-200 MV/mm². Lower Miyata grades indicate a better outcome (=fewer glistenings).

  4. Monocular Corrected Distance Visual Acuity (CDVA)

    Time frame: single study visit conducted 24 months after IOL implantation of the study eye

    Monocular Corrected Distance Visual Acuity (CDVA) was assessed for each study eye using a standardized visual acuity chart under photopic conditions with the subject's best refractive correction in place. CDVA was recorded in logarithm of the Minimum Angle of Resolution (logMAR), with typical values ranging from about -0.3 (approximately 20/10 Snellen acuity) to 1.0 (approximately 20/200 Snellen acuity), where lower logMAR scores indicate better vision.

Other outcomes

  1. Subjective Refraction (Spherical Equivalent)

    Time frame: single study visit conducted 24 months after IOL implantation of the study eye

    Subjective (manifest) refraction was performed under photopic conditions using standardized logarithmic visual acuity charts. For each study eye, manifest refraction was conducted to determine the best refractive correction. Sphere, cylinder, and axis were recorded, and spherical equivalent (SE) was calculated. SE values are reported in diopters (D). SE values closer to 0.00 D indicate a better refractive outcome (i.e., less residual myopia or hyperopia or astigmatism). An SE value within approximately ±0.50 D is generally considered a good refractive result.

Sponsors and collaborators

Lead sponsor

Carl Zeiss Meditec AG

Industry

Registry information

Official study title

A Non-interventional, Single-visit Study Focusing on the Evaluation of Glistening as Well as General Safety and Visual Outcomes With at Least 24 Months Follow-up in Patients Implanted With CT LUCIA 621P Intraocular Lenses

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Dec 22, 2025
Registry last updated
Aug 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.